Health: Antidepressant for COVID-19 reduces hospitalization risk, a new study finds
UC expert explains how the body responds to drugs like fluvoxamine
The anti-depressant drug fluvoxamine is being looked at by researchers as a possible treatment for COVID-19. A recently released study found the drug showed a reduced risk of hospitalization and death among COVID patients. However, the researchers concluded that more research is needed.
Health.com reported that experts believe fluvoxamine has shown to be effective against COVID-19 due to the medication's effects on the body's inflammatory response—specifically by tamping down that response in those with active COVID-19 infections.
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine/Photo/Colleen Kelley/UC Creative + Brand
Normally, when the body is trying to fight off an invader like SARS-CoV-2 (the virus that causes COVID-19), it releases cytokines, or biological chemicals that stimulate cell pathways and allow for communication between cells. Those cytokines signal to the body's immune system that it needs to start doing its job. In some cases, though, the the outpouring of cytokines becomes accelerated—known as a cytokine storm—creating high levels of inflammation in the body.
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine explained how that process works.
Normally, cytokines are meant to be helpful to us in moderation," said Fichtenbaum, "but when a certain pathway is engaged [too much] the immune system starts causing damage to the patient."
Lead image/CDC
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.